Hun Ju Lee, MD The University of Texas MD Anderson Cancer Center 5Live #ASCO2020
5:08
Key Insights on Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)
Chronic Lymphocytic Leukemia
Hun Ju Lee, MD The University of Texas MD Anderson Cancer Center 5Live #ASCO2020
Key Insights on Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)
Chronic Lymphocytic Leukemia Similar Videos
Similar Videos
-
Module 1: Ibrutinib for Hematologic Malignancies_Matthew Davids, MD, MMSc_Catherine Coombs_MD_Anthony Mato, MD, MSCE
9:28
-
Module 3_Treatment Strategies in the Relapsed Refractory Setting_Matthew Davids, MD, MMSc_Jeffrey Bubis, DO, FACOI, FACP_Divis Khaira, MD
11:17
-
Module 3: Zanubrutinib for Hematologic Malignancies_Matthew Davids, MD, MMSc_Catherine Coombs, Anthony Mato, MD, MSCE
7:59
